Zimmer Biomet Holdings, Inc. Share Price Berne S.E.

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Delayed Berne S.E. 5-day change 1st Jan Change
- CHF -.--% Intraday chart for Zimmer Biomet Holdings, Inc. -.--% -.--%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 7.76B 6.91B 607B Sales 2025 * 8.12B 7.22B 635B Capitalization 23.32B 20.75B 1,824B
Net income 2024 * 986M 877M 77.12B Net income 2025 * 1.19B 1.06B 92.91B EV / Sales 2024 * 3.56 x
Net Debt 2024 * 4.34B 3.86B 339B Net Debt 2025 * 3.03B 2.7B 237B EV / Sales 2025 * 3.25 x
P/E ratio 2024 *
23.3 x
P/E ratio 2025 *
20 x
Employees -
Yield 2024 *
0.85%
Yield 2025 *
0.86%
Free-Float 64.77%
More Fundamentals * Assessed data
Dynamic Chart
Osteal Therapeutics, Inc. announced that it has received $50 million in funding from Zimmer Biomet Holdings, Inc., Johnson & Johnson Innovation - JJDC, Inc., HM Capital Management, LLC, GIDEON STRATEGIC PARTNERS LLC and other investors CI
Zimmer Biomet Holdings Insider Sold Shares Worth $1,474,582, According to a Recent SEC Filing MT
Zimmer Biomet's Limited Exposure to High-Growth Markets Spurs Revenue Concerns, UBS Says MT
Barclays Adjusts Price Target on Zimmer Biomet to $125 From $130 MT
Barclays Adjusts Price Target on Zimmer Biomet Holdings to $125 From $130 MT
Zimmer Biomet Outlines Growth Strategy Through 2027; Board Approves $2 Billion Stock Buyback MT
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $2,000 million worth of its shares. CI
Transcript : Zimmer Biomet Holdings, Inc. - Analyst/Investor Day
Zimmer Biomet Holdings, Inc. authorizes a Buyback Plan. CI
Osteal Therapeutics, Inc. announced that it expects to receive funding CI
Argus Upgrades Zimmer Biomet to Buy From Hold With $150 Price Target MT
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024 CI
Raymond James Adjusts Price Target on Zimmer Biomet Holdings to $138 From $142 MT
UBS Adjusts Price Target on Zimmer Biomet Holdings to $112 From $109, Maintains Sell Rating MT
Truist Adjusts Zimmer Biomet Holdings' PT to $130 From $137, Keeps Hold Rating MT
More news

Latest transcript on Zimmer Biomet Holdings, Inc.

Managers TitleAgeSince
Chief Executive Officer 48 31/10/18
Director of Finance/CFO 55 30/06/19
Chief Tech/Sci/R&D Officer - 06/06/21
Members of the board TitleAgeSince
Director/Board Member 68 31/12/06
Director/Board Member 68 31/12/08
Director/Board Member 51 11/12/14
More insiders
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
113.4 USD
Average target price
136.4 USD
Spread / Average Target
+20.28%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW